CA-C3.AI
15.9.2020 15:02:13 CEST | Business Wire | Press release
C3.ai , a leading enterprise artificial intelligence (AI) software provider for accelerating digital transformation, today welcomes data scientists, developers, researchers, and creative thinkers from around the world to participate in the C3.ai™ COVID-19 Grand Challenge . The competition invites participants to leverage data science techniques in new and innovative ways to generate insights that previously were neither apparent nor achievable.
“The C3.ai COVID-19 Grand Challenge represents an opportunity to inform decision makers at the local, state, and federal levels and transform the way the world confronts this pandemic,” said Thomas M. Siebel, CEO of C3.ai. “As with the C3.ai COVID-19 Data Lake and the C3.ai Digital Transformation Institute , this initiative will tap our community’s collective IQ to make important strides toward necessary, innovative solutions that will help solve a global crisis.”
What Makes a Great Solution
In response to the acute challenges the world faces, the judging panel will prioritize data science projects that help us understand and mitigate the spread of the virus; improve the response capabilities of the medical community; minimize the impact of this disease on society; and help policymakers navigate responses to COVID-19.
Projects may address, but are not limited to:
- Applying machine learning and other AI methods to mitigate the spread of the COVID-19 pandemic
- Genome-specific COVID-19 medical protocols, including precision medicine of host responses
- Biomedical informatics methods for drug design and repurposing
- Design and sharing of clinical trials for collecting data on medications, therapies, and interventions
- Modeling, simulation, and prediction for understanding COVID-19 propagation and efficacy of interventions
- Logistics and optimization analysis for design of public health strategies and interventions
- Rigorous approaches to designing sampling and testing strategies
- Data analytics for COVID-19 research harnessing private and sensitive data
- Improving societal resilience in response to the spread of the COVID-19 pandemic
- Broader efforts in biomedicine, infectious disease modeling, response logistics and optimization, public health efforts, tools, and methodologies around the containment of rising infectious diseases and response to pandemics.
Award Criteria
A panel of judges will evaluate submissions on the extent to which they derive insights, leveraging data science techniques (e.g., statistical analyses, AI/ML algorithms, optimization approaches, etc.) that were not obvious before.
- Pat House, Vice Chairman, C3.ai
- Mike Callagy, County Manager, County of San Mateo
- Richard Levin, Board of Directors, C3.ai and Former President Emeritus, Yale University
- S. Shankar Sastry, Co-Director, C3.ai Digital Transformation Institute and Professor of Electrical Engineering & Computer Sciences, UC Berkeley
- Zico Kolter, Associate Professor of Computer Science, Carnegie Mellon University
The competition is now open with a registration deadline of Oct. 25 and a submission deadline of Nov. 18, 2020. To learn more about how to submit proposals, please visit https://c3.ai/grand-challenge/ .
By Dec. 9, 2020, C3.ai will announce seven competition winners and award $200,000 in cash prizes to the honorees.
- Prizes – There will be one Grand Prize of $100,000, two second-place awards of $25,000 each, and four third-place awards of $12,500 each.
- Publication – The winners will have their work published by C3.ai.
C3.ai COVID-19 Data Lake Expands
The C3.ai™ COVID-19 Data Lake , launched in April 2020, continues to expand and now consists of 40 unique datasets, making it the largest unified, federated image of COVID-19 data in the world. Researchers and developers worldwide can access this free, open-source resource to build models, run analytics, develop tools, and more, without the time and effort of data wrangling.
As part of the C3.ai COVID-19 Grand Challenge, applicants will be required to use the C3.ai COVID-19 Data Lake as a resource to generate new and innovative solutions.
The latest datasets to be integrated into the Data Lake include:
- CDC: Weekly Updates by Select Demographic Characteristics
- COVID Racial Data Tracker from the COVID Tracking Project at The Atlantic
- US Census Bureau: County Population by Age, Sex, Race and Hispanic Origin
- US Bureau of Labor Statistics: County Unemployment Statistics
- Realtor.com: Housing Indicators
- Bureau of Economic Analysis: GDP and Economic Profile by County
- Opportunity Insights: Economic Tracker
- Swayable and TapResearch: COVID-19 Tracker Poll
For additional information about the C3.ai COVID-19 Data Lake, please visit: https://c3.ai/covid
To learn more about the C3.ai COVID-19 Grand Challenge, please visit https://c3.ai/grand-challenge/ .
About C3.ai
C3.ai is a leading AI software provider for accelerating digital transformation. C3.ai delivers the C3 AI® Suite for developing, deploying, and operating large-scale AI, predictive analytics, and IoT applications in addition to an increasingly broad portfolio of turnkey AI applications. The core of the C3.ai offering is a revolutionary, model-driven AI architecture that dramatically enhances data science and application development.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005410/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom